Skip to main content
Menu

AlphaLISA SureFire Ultra Human and Mouse Total STAT2 Detection Kit, 100 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Total STAT2 assay is a sandwich immunoassay for quantitative detection of total STAT2 in cellular lysates using Alpha Technology.

Feature Specification
Application Cell Signaling
Protocol Time 2h at RT
Sample Volume 30 µL

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Total STAT2 assay is a sandwich immunoassay for quantitative detection of total STAT2 in cellular lysates using Alpha Technology.

Product variants
Unit Size: 100 Assay Points
Part #:
ALSU-TST2-A-HV
List price
USD 722.00
Your online price:
Unit Size: 500 Assay Points
Part #:
ALSU-TST2-A500
List price
USD 2,441.00
Your online price:
Unit Size: 10,000 Assay Points
Part #:
ALSU-TST2-A10K
List price
USD 14,688.00
Your online price:
Unit Size: 50,000 Assay Points
Part #:
ALSU-TST2-A50K
List price
USD 46,690.00
Your online price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Loading...

Overview

Signal Transducer and Activator of Transcription 2 (STAT2) is a transcription factor that primarily mediates type I and type III interferon (IFN) signaling, playing a central role in establishing antiviral defenses. Upon IFN stimulation, receptor‑associated JAK1 and TYK2 phosphorylate STAT2 (and STAT1). Phosphorylated STAT2 heterodimerizes with STAT1 and associates with IRF9 to form the ISGF3 complex, which binds interferon‑stimulated response elements (ISREs) to induce interferon‑stimulated genes (ISGs), including OAS, PKR (EIF2AK2), and MX1/MX2.

Unlike several other STATs, STAT2 does not bind DNA as a homodimer and exerts most transcriptional functions within ISGF3. In STAT1‑limited contexts, STAT2 can partner with IRF9 to drive a STAT2–IRF9 (ISGF3‑like) response, extending antiviral gene induction.

STAT2 deficiency in humans causes marked susceptibility to viral infections (notably many respiratory RNA viruses, and some DNA viruses), often with severe disease after live‑attenuated vaccines, underscoring STAT2’s non‑redundant role in IFN signaling. Consistently, numerous viruses (e.g., paramyxoviruses, flaviviruses, orthomyxoviruses) encode proteins that degrade, sequester, or block STAT2, highlighting STAT2 as a major target of viral immune evasion.

Because STAT2 tunes IFN pathway amplitude and duration, it represents a potential therapeutic node to enhance antiviral responses or attenuate pathogenic IFN signaling in selected auto‑inflammatory and autoimmune settings.

The AlphaLISA SureFire Ultra Human and Mouse Total STAT2 Detection Kit is a sandwich immunoassay for the quantitative detection of total STAT2 in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • High-throughput screening for preclinical studies

How it works

Total-AlphaLISA SureFire Ultra assay principle

The Total-AlphaLISA SureFire Ultra assay measures the expression level of a protein target in a cell lysate.

The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.

assay-principle-Total-AlphaLISA-Surefire-Ultra.jpg

 

Total-AlphaLISA SureFire Ultra two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

2 plates assay protocol AlphaLISA Surefire Ultra Total assay

Total-AlphaLISA SureFire Ultra one-plate assay protocol

Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.

1-plate-assay-protocol-AlphaLISA-Surefire-Ultra-Total-assay

Assay validation

STAT2 activation mediated by Type I Interferons

A431 cells were seeded in a 96-well plate (60,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of IFNβ for 30 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2 Phospho (Tyr690) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 6,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, IFNβ triggered a dose-dependent increase in the levels of Phospho STAT2 (Tyr690) with a modest decrease in Total levels (2.8 fold).

Pharmacological Validation of STAT2
Pharmacological Validation of STAT2
Pharmacological Validation of STAT2

 

Decrease of STAT2 phosphorylation by Ruxolitnib

THP-1 cells were seeded in a 96-well plate (200,000 cells/well) in HBSS containing 10 ng/mL IFNβ for 15 minutes at 37°C, 5% CO2. The cells were then treated with increasing concentrations of JAK inhibitor, Ruxolitinib for a further 1 hour.

After treatment, the cells were spun at 1200 rpm for 5 minutes and lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). STAT2 Phospho (Tyr690) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 20,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Inhibition of JAK1 signaling mediated by Ruxolitinib, resulted in a decrease of phosphorylated STAT2 after 1 hour while STAT2 Total levels remained unchanged.

Pharmacological Validation of STAT2

Assay versatility

Evaluation of STAT2 Total levels in PBMCs

Peripheral Blood Mononuclear Cells (PBMCs) were isolated from healthy donors using Ficoll Plaque Plus (Merck GE17-1440-02). PBMCs were lysed at 6 x 106 cells/mL with Lysis Buffer for 10 minutes at RT with shaking. Lysate was serially diluted in Lysis Buffer and evaluated for STAT2 Total levels using the AlphaLISA SureFire Ultra kit.

For the detection step, 10 µL of cell lysate (starting at approximately 60,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings. Dotted line represents assay background.

Pharmacological Validation of Total STAT2

Expression of STAT2 in various cell lines

Adherent cell lines were seeded in a 96-well plate (40,000 cells/well) and incubated overnight at 37°C, 5% CO2. Cells were lysed with 100 µL of Lysis Buffer at RT with shaking (350 rpm). Suspension cell lines were seeded in a 96-well plate (400,000 cells/well) in HBSS + 0.1% BSA and then lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm).

STAT2 levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate (approximately 4,000 adherent cells and 40,000 suspension cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

STAT2 is expressed in a wide variety of cell lines. High levels of expression were detected in PC3, A431 and RPMI 8226 cells.

Versatility of Total STAT2 assay

Assay sensitivity

Assay sensitivity - cell lysate dilution

Cell lysate was prepared from A431 cells cultured to confluency in T175 flasks. Cells were treated with 10 ng/mL IFNβ for 30 minutes and then lysed in 4 mL of Lysis Buffer.

Lysate was serially diluted in Lysis Buffer and STAT2 levels were evaluated using the AlphaLISA SureFire Ultra kit. For the detection step, 10 µL of lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Approximate number of cells/datapoint is indicated on the graph. The dotted line represents assay background. The assay can detect Total STAT2 in less than 300 cells.

Sensitivity of STAT2 Total assay

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Product Group
Kit
Protocol Time
2h at RT
Sample Volume
30 µL
Shipping Conditions
Shipped in Blue Ice
Target
STAT2
Target Class
Phosphoproteins
Target Species
Human
Mouse
Technology
Alpha
Therapeutic Area
Autoimmunity
Inflammation
Oncology
Virology
Unit Size
100 Assay Points

Resources

Are you looking for resources, click on the resource type to explore further.

1-4 of 4 Resources
Brochure Icon
Brochure
Alpha assays and reagents catalog

Alpha technolgy enables the rapid and straightforward mesaure of virtually any target. This includes enzymes, receptor-ligand...

Guide Icon
Guide
AlphaLISA SureFire Ultra: the ultimate guide for successful experiments

The definitive guide for setting up a successful AlphaLISA SureFire Ultra assay

Several biological processes are regulated by...

Brochure Icon
Brochure
Alpha SureFire Ultra no-wash immunoassay catalog

Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...

Brochure Icon
Brochure
Species compatibility for HTRF, AlphaLISA SureFire Ultra and Alpha SureFire Ultra Multiplex assays

This document includes detailed tables listing HTRF™, AlphaLISA™ SureFire® Ultra™, and Alpha SureFire® Ultra™ Multiplex assays...

Loading...

Scroll Icon

Revvity AI Assistant Beta